Danish Hospitality Stock News

How NKT’s latest earnings and guidance update set the stage NKT (CPSE:NKT) reported second quarter 2026 earnings that were close to the prior year, alongside six month figures that showed similar stability in sales and net income. On the same day, the company also narrowed its 2026 revenue outlook to a range of €2.65b to €2.75b, compared with earlier guidance of €2.63b to €2.78b. This gave investors a more focused view of expected activity levels for the rest of the year. See our latest...

As the European market navigates a landscape marked by resilient economic data and geopolitical uncertainties, the STOXX Europe 600 Index recently closed slightly lower, reflecting investor caution amid these mixed signals. Despite these challenges, opportunities may exist for investors seeking undervalued stocks that could benefit from current sector shifts and regional economic resilience. In this context, identifying stocks trading below their estimated value can be particularly appealing...

A.P. Møller - Mærsk A/S ( CPH:MAERSK B ) just released its quarterly report and things are looking bullish. A.P. Møller...

Shareholders of DFDS A/S ( CPH:DFDS ) will be pleased this week, given that the stock price is up 19% to kr.155...

It's been a good week for NKT A/S ( CPH:NKT ) shareholders, because the company has just released its latest half-year...

It's been a good week for Solar A/S ( CPH:SOLAR B ) shareholders, because the company has just released its latest...

Aktieselskabet Schouw went into this report with the stock at DKK680 after a solid run over the past month, and the market is now weighing whether that optimism matches the earnings reality. The headline is clear: Q2 2026 delivered a sharp jump in profitability, with basic earnings per share at DKK14.18 and net income at DKK321m, both well ahead of Q1. In addition, management lifted full year revenue and EBITDA guidance for 2026, which puts the focus firmly on whether this improvement looks...

Tivoli stock closed at DKK632 after Q2 2026 earnings, roughly flat in recent weeks, yet the numbers behind that calm surface tell a more demanding story. The headline is valuation strain. The shares trade on a P/E of 31.6x while the wider European hospitality industry sits at 18.5x and peers at 14.2x. At the same time, trailing 12 month earnings growth is 1.9% with a net margin of 8.4%. That combination leaves investors paying a clear premium today and raises the question of how much future...

Global bond yields have pushed higher as inflation expectations adjust, which has pressured long term rates and made dependable cash flows more valuable in pricing models. When markets focus on macro swings, stocks with solid projected cash generation that also trade below fair value can get overlooked. This article highlights 3 stocks from the Undervalued Stocks Based On Cash Flows screener that stand out on this theme. The 3 stocks highlighted below are just a small sample, since the full...

FLSmidth (CPSE:FLS) stock is back in focus after the company named Petri Virrankoski as President of its Service Business Line, with a planned 2027 start. The appointment underscores attention on the service segment. See our latest analysis for FLSmidth. The leadership news comes at a time when FLSmidth’s recent momentum has been positive. The 1 month share price return is 6.38% and the 1 year total shareholder return is 27.11%. In addition, the 5 year total shareholder return of 155.07%...

Novo Nordisk (CPSE:NOVO B) has entered an AI-focused partnership with H1 to support clinical trial operations. The collaboration uses H1's proprietary AI-ready data and clinical development workflows to support drug development. The agreement is aimed at improving clinical trial design, execution and site or investigator selection through data driven insights. This kind of AI partnership in drug development sits within a wider shift toward digital and data infrastructure. It is worth...

Novozymes (CPSE:NSIS B) drew fresh attention on 12 August 2026 after Novonesis launched Optiva Triticum, a biosolution designed to give pasta producers more flexibility in wheat sourcing while preserving texture and firmness. See our latest analysis for Novozymes. At a share price of DKK424.6, Novozymes has seen a 12.27% 90 day share price return and a 49.03% three year total shareholder return. This may point to momentum that product launches like Optiva Triticum may be influencing as...

A.P. Møller - Mærsk (CPSE:MAERSK B) just released its second quarter 2026 results, reporting sales of US$15.76b and net income of US$1.26b, alongside an upgraded full year earnings outlook. See our latest analysis for A.P. Møller - Mærsk. The upgraded guidance and earnings beat have coincided with a sharp re‑rating of A.P. Møller - Mærsk, with a 40.9% year to date share price return and a 51.2% one year total shareholder return. This suggests momentum has been building as investors reassess...

Ørsted stock went into this earnings release under pressure, with the share price down about 14% over the past three months and trading at DKK139.2 at Thursday’s close. The market has been wrestling with an unprofitable trailing year and questions about how the balance sheet will fund a heavy offshore build out. The headline from this quarter is not the income statement. It is the funding capacity. Net debt of DKK22b, a liquidity reserve above DKK115b and a funds from operations to adjusted...

A.P. Møller - Mærsk stock went into this earnings print with a strong run, up about 30% over the past three months and firmly in recovery-story territory. The latest numbers now test that optimism. The headline is profit pressure. Trailing net profit margin sits at 3% compared with 12.6% a year earlier, even as revenue over the last twelve months totals about US$53.6b. The market is weighing a richer P/E of 26.3x against this thinner profitability. This makes this quarter less about volume...

Zealand Pharma stock came into today on a strong run, up 22% over the past month and 10% over three months, with investors leaning into its low 3.7x P/E and fresh profitability over the last year. The earnings release keeps that tension front and center. H1 revenue landed at DKK 4.5b, powered by a DKK 3.7b Phase III milestone and a DKK 798m payment from Roche, and management highlighted DKK 14.5b of cash on hand. The question now is how long that earnings and cash firepower can support the...

Netcompany Group (CPSE:NETC) reported second quarter 2026 earnings on 13 August, with both sales and net income higher than the prior year. The announcement gives investors fresh numbers to reassess the stock. See our latest analysis for Netcompany Group. Netcompany Group's latest earnings update comes after a mixed price pattern, with the share price up 6.2% over the past month yet down 6.4% year to date, while the 1 year total shareholder return of 38.0% and 3 year total shareholder return...

European equities have recently experienced a boost, with the pan-European STOXX Europe 600 Index climbing 1.70% due to improved risk appetite and resilient earnings, despite ongoing geopolitical uncertainties. In this environment of cautious optimism, identifying undervalued stocks can be a strategic move for investors seeking opportunities that are priced below their estimated worth.

Russia’s war in Ukraine has turned European energy into a pressure point again, with supply routes, winter demand and sanctions all back in focus. That mix of risk and rearranged trade flows can quickly change how investors look at European Energy Sector stocks. This article walks through three stocks from our screener that appear positively exposed to the latest news, and explains what makes each one worth a closer look now. The three European energy stocks highlighted below are just a...

It's been a good week for Genmab A/S ( CPH:GMAB ) shareholders, because the company has just released its latest...

Novo Nordisk stock is back under the microscope after a weak three year share price run, even as its valuation checks screen it as attractively priced on several fronts. Recent setbacks in parts of the drug pipeline have weighed on sentiment, while strong demand for obesity treatments keeps investors focused on what the current price actually implies. The share price has fallen 46.9% over the past three years, which means anyone buying today is doing so after a sizeable reset in market...

What Ørsted’s Old 300 Storage milestone means for the stock Ørsted (CPSE:ORSTED) has brought its Old 300 Storage battery project in Needville, Texas, into commercial operation, connecting 250 MW of storage capacity to the ERCOT grid alongside the existing Old 300 Solar facility. This expansion in U.S. battery energy storage, supplied by Tesla Megapacks and paired with one of the larger U.S. solar projects commissioned in 2024, gives investors fresh context for assessing Ørsted’s role in large...

In July 2026, Genmab A/S and AbbVie clarified that the Phase 3 EPCORE DLBCL-1 trial of epcoritamab in relapsed or refractory diffuse large B-cell lymphoma did not achieve a statistically significant improvement in overall survival, the sole primary endpoint in the United States. This clarification highlights the complexity of region-specific trial endpoints and leaves investors waiting for detailed peer-reviewed data to understand epcoritamab’s broader clinical profile. We’ll now examine how...

In recent weeks, global markets have been navigating a complex landscape marked by rising oil prices, geopolitical tensions in the Middle East, and fluctuating investor sentiment around AI investments. Amid these challenges, major indices like the Nasdaq Composite and S&P 500 have faced declines, while European markets showed resilience with modest gains. In such an environment, identifying undervalued stocks can be crucial for investors seeking opportunities that may offer potential...